ML22230B868
| ML22230B868 | |
| Person / Time | |
|---|---|
| Site: | SHINE Medical Technologies |
| Issue date: | 08/16/2022 |
| From: | Public Commenter Public Commenter |
| To: | NRC/NMSS/DREFS |
| NRC/NMSS/DREFS | |
| References | |
| 87FR40868 | |
| Download: ML22230B868 (6) | |
Text
From: Jeffrey Bartelme <jeffbartelme@shinefusion.com>
Sent: Tuesday, August 16, 2022 3:57 PM To: SHINEEnvironmental.Resource
Subject:
[External_Sender] 2022-SMT-0094, "SHINE Technologies, LLC Comments on NUREG-2183, Supplement 1, Environmental Impact Statement Related to the Operating License for the SHINE Medical Isotope Production Facility (Draft Report for Comment) (Docket ID N...
Attachments: 2022-SMT-0094.pdf SHINE hereby submits 2022-SMT-0094, "SHINE Technologies, LLC Comments on NUREG-2183, Supplement 1, Environmental Impact Statement Related to the Operating License for the SHINE Medical Isotope Production Facility (Draft Report for Comment) (Docket ID NRC-2022-0135)". Please let me know if you have any questions on the attached. Thank you.
Jeff Bartelme Director of Licensing SHINE Technologies 3400 Innovation Ct.
Janesville, WI 53546 O: +1.608.210.1735 M: +1.920.652.6287 jeffbartelme@shinefusion.com SHINEfusion.com This message and accompanying documents are covered by the Electronic Communications Privacy Act, 18 U.S.C. §§ 2510-2521, and may contain confidential information for the specified individual(s) only. If you are not the intended recipient, you are hereby notified that you have received this document in error and that any review, dissemination, copying, or the taking of action based on the contents of this information is strictly prohibited. If you have received this communication in error, please notify the sender immediately by e-mail, and delete the message.
Federal Register Notice: 87FR40868 Comment Number: 2 Mail Envelope Properties (DM5PR2201MB14508357E0EBA7BABA102870CF6B9)
Subject:
[External_Sender] 2022-SMT-0094, "SHINE Technologies, LLC Comments on NUREG-2183, Supplement 1, Environmental Impact Statement Related to the Operating License for the SHINE Medical Isotope Production Facility (Draft Report for Comment) (Docket ID N...
Sent Date: 8/16/2022 3:57:05 PM Received Date: 8/16/2022 3:57:14 PM From: Jeffrey Bartelme Created By: jeffbartelme@shinefusion.com Recipients:
"SHINEEnvironmental.Resource" <Shine.Environmental@nrc.gov>
Tracking Status: None Post Office: DM5PR2201MB1450.namprd22.prod.outlook.com Files Size Date & Time MESSAGE 1241 8/16/2022 3:57:14 PM image001.png 2799 2022-SMT-0094.pdf 555102 Options Priority: Normal Return Notification: No Reply Requested: No Sensitivity: Normal Expiration Date:
August 16, 2022 2022-SMT-0094 Via E-mail to: SHINEEnvironmental@nrc.gov Office of Administration Mail Stop: OWFN-7-A60M U.S. Nuclear Regulatory Commission Washington, DC 20555-0001 ATTN: Program Management, Announcements and Editing Staff
References:
(1) U.S. Nuclear Regulatory Commission, Environmental Impact Statement Related to the Operating License for the SHINE Medical Isotope Production Facility (Draft Report for Comment), NUREG-2183, Supplement 1, June 2022 (ML22179A346)
SHINE Technologies, LLC Comments on NUREG-2183, Supplement 1, Environmental Impact Statement Related to the Operating License for the SHINE Medical Isotope Production Facility (Draft Report for Comment) (Docket ID NRC-2022-0135)
SHINE Technologies, LLC (SHINE) appreciates the opportunity to comment on NUREG-2183, Supplement 1, the draft supplement to the environmental impact statement (EIS) related to the operating license for the SHINE medical isotope production facility (Reference 1).
Enclosure 1 provides the SHINE comments on NUREG-2183, Supplement 1. SHINE has determined that these comments are administrative because they do not affect the conclusions provided in NUREG-2183, Supplement 1.
If you have any questions, please contact Mr. Jeff Bartelme, Director of Licensing, at 608/210-1735.
Very truly yours, James Costedio Vice President of Regulatory Affairs and Quality SHINE Technologies, LLC Docket No. 50-608 Enclosure cc: Project Manager, USNRC Environmental Project Manager, USNRC 3400 Innovation Ct
- Janesville, WI 53546
- 877.512.6554
- info@shinemed.com
- www.SHINEtechnologies.com
ENCLOSURE 1 SHINE TECHNOLOGIES, LLC SHINE TECHNOLOGIES, LLC COMMENTS ON NUREG-2183, SUPPLEMENT 1, ENVIRONMENTAL IMPACT STATEMENT RELATED TO THE OPERATING LICENSE FOR THE SHINE MEDICAL ISOTOPE PRODUCTION FACILITY (DRAFT REPORT FOR COMMENT) (DOCKET ID NRC-2022-0135)
Section 1.0 - Introduction Page 1-1, Line 21 Recommend referencing the most recent supplement to the July 17, 2019 application for an operating license, submitted by SHINE on July 26, 2022 (Reference 1).
Section 2.0 - Proposed Federal Action Page 2-2, Line 9 SHINE revised the approximate total facility footprint to be 375,000 square feet (ft2) (35,000 square meters [m2]) via Reference 2.
Recommend revising accordingly.
Page 2-2, Line 36 SHINE revised the approximate total facility footprint to be 375,000 ft2 (35,000 m2) via Reference 2. Recommend revising accordingly.
Page 2-6, Line 24 SHINE revised the Environmental Report (ER) Supplement via Reference 3 to reflect the renumbering of the Janesville City Ordinances.
Janesville City Ordinance 13.16 has been renumbered to Janesville City Ordinance 40-170. Recommend revising accordingly.
Section 3.0 - Affected Environment and Environmental Consequences Page 3-8, Line 20 A description of the likelihood of whooping cranes to appear on the SHINE site was provided via the SHINE Response to RAI SSS-2 (Reference 3). Recommend revising the reference citation from (SHINE 2022d) to (SHINE 2020a).
Page 3-16, Line 29 SHINE estimated the total number of annual medical isotope shipments to be 520 via the SHINE Response to RAI PA-7 (Reference 3).
Recommend revising accordingly.
Page 3-19, Line 7 Typographical error. Recommend replacing decreased from 26.5 with decreased from 25.6.
Page 3-23, Line 6 SHINE identified three chemicals (i.e., rhodium chloride, uranyl peroxide, and uranyl sulfate) which do not have published Protective Action Criteria (PAC) values in Section 13b.3 of the FSAR (Reference 4). Recommend revising accordingly.
Page 1 of 2
Page 3-23, Line 25 Typographical error in the Nearest Resident Concentration for Ammonium Hydroxide. Recommend replacing 1.89E with 1.89E-03.
Page 3-23, Line 25 Typographical error in the Source Term for Uranyl Peroxide. Recommend replacing 13.68 with 1368.
References
- 1. SHINE Technologies, LLC letter to NRC, dated July 26, 2022, SHINE Technologies, LLC Application for an Operating License Supplement No. 29 (ML22207A006)
- 2. SHINE Medical Technologies, LLC letter to NRC, dated January 22, 2021, SHINE Medical Technologies, LLC Application for an Operating License Response to Environmental Requests for Additional Information (ML21022A027)
- 3. SHINE Medical Technologies, LLC letter to NRC, dated March 13, 2020, SHINE Medical Technologies. LLC Application for an Operating License Response to Environmental Requests for Additional Information (ML20073E880)
- 4. SHINE Technologies, LLC letter to NRC, dated January 26, 2022, SHINE Technologies, LLC Application for an Operating License Supplement No. 14 (ML22034A612)
Page 2 of 2